Mirion Technologies Appoints Michael Rossi as President of Mirion Medical
October 03 2022 - 8:00AM
Business Wire
Mirion Technologies, Inc. (“Mirion,” “we” or the “Company”)
(NYSE: MIR), a global provider of radiation detection, measurement,
analysis and monitoring solutions to the medical, nuclear, defense,
and research end markets, today announced the appointment of
Michael Rossi as the President of Mirion Medical. Michael will
report directly to Mirion’s CEO, Tom Logan, who had been acting as
President of the business segment.
Michael joins Mirion from Novartis, where he most recently
served as the Head of Radioligand Imaging for the Advanced
Accelerator Applications business. Prior to Novartis, Michael spent
five years at Jubilant Pharma where he served in several different
roles with increasing levels of responsibility. Michael also brings
experience from GE Healthcare, Tyco Healthcare/Mallinckrodt and
Syncor International to the Mirion team. Michael earned a Bachelor
of Science in Pharmacy degree from the University of the Sciences –
Philadelphia College of Pharmacy and carries the Authorized Nuclear
Pharmacist Certification from Butler University. Michael has also
served on several Boards of Directors and remains a Licensed
Pharmacist in the state of Pennsylvania.
“I am thrilled to welcome Michael to the Mirion team,” said Tom
Logan, Mirion’s CEO. “Michael has a unique blend of domain
experience and leadership qualities in the nuclear medicine space.
His appointment comes at an exciting time for the Company, as we
aim to drive organic and inorganic growth and margin expansion
across our medical business. I am confident that Michael will
accelerate the attainment of our healthcare ambitions.”
“I am incredibly excited to be joining Mirion Medical at such an
impactful time in the Company’s growth trajectory,” added Michael
Rossi. “What Tom and the team have built over the last few years is
truly impressive and I look forward to building off the solid
momentum with my new colleagues.”
About Mirion
Mirion Technologies is a leading provider of detection,
measurement, analysis and monitoring solutions to the nuclear,
defense, medical and research end markets. The organization aims to
harness its unrivaled knowledge of ionizing radiation for the
greater good of humanity. Headquartered in Atlanta (GA – USA),
Mirion employs around 2,800 people and operates in 13 countries.
For more information, and for the latest news and content from
Mirion, visit ir.mirion.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221003005192/en/
For investor inquiries: Jerry Estes ir@mirion.com For
media inquiries: Matthew Maddox mmaddox@mirion.com
Mirion Technologies (NYSE:MIR)
Historical Stock Chart
From May 2024 to Jun 2024
Mirion Technologies (NYSE:MIR)
Historical Stock Chart
From Jun 2023 to Jun 2024